Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway. [electronic resource]
Producer: 20160614Description: 350-355 p. digitalISSN:- 1090-2104
- Animals
- Antineoplastic Agents -- administration & dosage
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Humans
- Mefloquine -- administration & dosage
- Mice
- Mice, SCID
- Molecular Targeted Therapy -- methods
- Oncogene Protein v-akt -- metabolism
- Phosphatidylinositol 3-Kinases -- metabolism
- Phosphoric Monoester Hydrolases -- metabolism
- Signal Transduction -- drug effects
- Stomach Neoplasms -- drug therapy
- TOR Serine-Threonine Kinases -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.